Heart failure & cardiomyopathiesMeta-analysis
Glucagon-Like Peptide-1 Receptor Agonists Reduce Atrial Fibrillation Among Patients with Heart Failure with Preserved and Mildly Reduced Ejection Fraction – a Meta-Analysis of Randomized Controlled Trials
- Systematic review and meta-analysis of randomised trials
- fixed-effect model
Authors' conclusion
Glucagon-like peptide-1 receptor agonist therapy is associated with a significant reduction in incident AF among patients with HFpEF and HFmrEF.
Study context
- Population
- Patients with heart failure with preserved ejection fraction (HFpEF) or HF with mildly reduced EF (HFmrEF)
- Participants
- 3,743 patients · 4 RCTs
- Comparison
- GLP-1 RA vs control
Pooled result
Incident atrial fibrillation (AF)
Relative risk
0.54
95% CI 0.36–0.81
P = 0.003
GLP-1 RA vs Control
RR 0.54 (95% CI 0.36–0.81); P = 0.003
As reported in the abstract
Further pooled results
Body weight, SBP, left atrial volume
- Significantly greater reductions with GLP-1 RA
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Glucagon-Like Peptide-1 Receptor Agonists Reduce Atrial Fibrillation Among Patients with Heart Failure with Preserved and Mildly Reduced Ejection Fraction – a Meta-Analysis of Randomized Controlled Trials. Eur J Heart Fail. Published 11 November 2025. doi:10.1002/ejhf.70085
Summarised from the published abstract; every number is checked against it